The FDA has approved a onceaday pill that combines two drugs to treat hepatitis C the deadly virus that attacks the liver and is believed to infect  million Americans The new product brings several advances but it also has a steep price tag reported at  per tablet NPRs Michaeleen Doucleff reports Announcing the   Friday the Californiabased Gilead Sciences included this quote from Dr Nezam Afdhal the director of hepatology at Beth Israel Deaconess Medical Center who was involved in the clinical trials The pills maker reported billions of dollars in sales of a related drug that was approved last year One of the components of Harvoni is that drug called Sovaldi which Gilead Sciences also makes As   earlier this year Sovaldis aday price tag helped the company break a sales record for a new drug when it reported selling  billion worth of Sovaldi in the quarter that ended March  We didnt really say We want to charge  a pill  Gilead executive Gregg Alton has said of Sovaldis price Were just looking at what we think was a fair price for the value that were bringing into the health care system and to the patients In a   Shots noted that Medicare had shifted its policies to cover Sovaldi following hepatitis C treatment guidelines from the medical community The move came days after   the story of an Arizona man who was on the verge of developing cirrhosis  and couldnt afford the  Sovaldi and another drug would cost A representative of the Centers for Medicare and Medicaid Services contacted NPR to say that changing the agencys coverage policies has been a slow process Speaking about the new regimen yesterday Dr Edward Cox of the FDAs Center for Drug Evaluation and Research said With the development and approval of new treatments for hepatitis C virus we are changing the treatment paradigm for Americans living with the disease